Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBRX4
- Development stage
- Preclinical
- Lead developer
- Stramsen Biotech
- Modality
- Small Molecules
01
Overview
SBRX4 is a plant-based drug candidate developed by Stramsen Biotech, Inc. for the treatment of gout and joint pains. It is part of the company's SBRX series of botanical therapeutics, which are derived from plant sources. Stramsen Biotech focuses on developing natural drug candidates as alternatives or adjuncts to synthetic pharmaceuticals across various therapeutic areas, including inflammation and oncology. While the specific botanical composition and molecular mechanism of action for SBRX4 have not been publicly disclosed, it is positioned within the company's pipeline as a treatment for inflammatory joint conditions. The drug is currently in the early stages of development.
Beyond the preview
Go deeper on SBRX4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBRX4.